Cargando…

Anesthesia for muscle biopsy to test susceptibility to malignant hyperthermia

INTRODUCTION: Malignant hyperthermia is an autosomal dominant pharmacogenetic disorder, characterized by hypermetabolic crisis triggered by halogenated anesthetics and/or succinylcholine. The standard method for diagnosing malignant hyperthermia susceptibility is the in vitro muscle contracture test...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva, Helga Cristina Almeida da, Onari, Elton Shinji, Castro, Isac de, Perez, Marcelo Vaz, Hortensi, Alexandre, Amaral, José Luiz Gomes do
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391910/
https://www.ncbi.nlm.nih.gov/pubmed/31053363
http://dx.doi.org/10.1016/j.bjane.2019.02.003
_version_ 1784770957146062848
author Silva, Helga Cristina Almeida da
Onari, Elton Shinji
Castro, Isac de
Perez, Marcelo Vaz
Hortensi, Alexandre
Amaral, José Luiz Gomes do
author_facet Silva, Helga Cristina Almeida da
Onari, Elton Shinji
Castro, Isac de
Perez, Marcelo Vaz
Hortensi, Alexandre
Amaral, José Luiz Gomes do
author_sort Silva, Helga Cristina Almeida da
collection PubMed
description INTRODUCTION: Malignant hyperthermia is an autosomal dominant pharmacogenetic disorder, characterized by hypermetabolic crisis triggered by halogenated anesthetics and/or succinylcholine. The standard method for diagnosing malignant hyperthermia susceptibility is the in vitro muscle contracture test in response to halothane-caffeine, which requires muscle biopsy under anesthesia. We describe a series of anesthetic procedures without triggering agents in malignant hyperthermia, comparing peripheral nerve block and subarachnoid anesthesia. METHOD: We assessed the anesthetic record charts of 69 patients suspected of malignant hyperthermia susceptibility who underwent muscle biopsy for in vitro muscle contracture in the period of 7 years. Demographic data, indication for malignant hyperthermia investigation, in vitro muscle contracture test results, and surgery/anesthesia/recovery data were analyzed. RESULTS: Sample with 34 ± 13.7 years, 60.9% women, 65.2% of in vitro muscle contracture test positive. Techniques used: peripheral nerve blocks — lateral femoral and femoral cutaneous, latency 65 ± 41 min — (47.8%); subarachnoid anesthesia (49.3%), and total venous anesthesia (1.4%). There was 39.4% failure of peripheral nerve block and 11.8% of subarachnoid anesthesia. Adverse events (8.7%) occurred only with subarachnoid blockade (bradycardia, nausea, and transient neurological syndrome). All patients remained in the post-anesthesia care unit until discharge. Age and weight were significantly higher in patients with blockade failure (ROC cut-off point of 23.5 years and 59.5 kg) and blockade failure was more frequent in the presence of increased idiopathic creatine kinase. CONCLUSION: Anesthesia with non-triggering agents has been shown to be safe in patients with malignant hyperthermia susceptibility. Variables such as age, weight, and history of increased idiopathic creatine kinase may be useful in selecting the anesthetic technique for this group of patients.
format Online
Article
Text
id pubmed-9391910
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-93919102022-08-21 Anesthesia for muscle biopsy to test susceptibility to malignant hyperthermia Silva, Helga Cristina Almeida da Onari, Elton Shinji Castro, Isac de Perez, Marcelo Vaz Hortensi, Alexandre Amaral, José Luiz Gomes do Braz J Anesthesiol Scientific Article INTRODUCTION: Malignant hyperthermia is an autosomal dominant pharmacogenetic disorder, characterized by hypermetabolic crisis triggered by halogenated anesthetics and/or succinylcholine. The standard method for diagnosing malignant hyperthermia susceptibility is the in vitro muscle contracture test in response to halothane-caffeine, which requires muscle biopsy under anesthesia. We describe a series of anesthetic procedures without triggering agents in malignant hyperthermia, comparing peripheral nerve block and subarachnoid anesthesia. METHOD: We assessed the anesthetic record charts of 69 patients suspected of malignant hyperthermia susceptibility who underwent muscle biopsy for in vitro muscle contracture in the period of 7 years. Demographic data, indication for malignant hyperthermia investigation, in vitro muscle contracture test results, and surgery/anesthesia/recovery data were analyzed. RESULTS: Sample with 34 ± 13.7 years, 60.9% women, 65.2% of in vitro muscle contracture test positive. Techniques used: peripheral nerve blocks — lateral femoral and femoral cutaneous, latency 65 ± 41 min — (47.8%); subarachnoid anesthesia (49.3%), and total venous anesthesia (1.4%). There was 39.4% failure of peripheral nerve block and 11.8% of subarachnoid anesthesia. Adverse events (8.7%) occurred only with subarachnoid blockade (bradycardia, nausea, and transient neurological syndrome). All patients remained in the post-anesthesia care unit until discharge. Age and weight were significantly higher in patients with blockade failure (ROC cut-off point of 23.5 years and 59.5 kg) and blockade failure was more frequent in the presence of increased idiopathic creatine kinase. CONCLUSION: Anesthesia with non-triggering agents has been shown to be safe in patients with malignant hyperthermia susceptibility. Variables such as age, weight, and history of increased idiopathic creatine kinase may be useful in selecting the anesthetic technique for this group of patients. Elsevier 2019-07-31 /pmc/articles/PMC9391910/ /pubmed/31053363 http://dx.doi.org/10.1016/j.bjane.2019.02.003 Text en © 2019 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Scientific Article
Silva, Helga Cristina Almeida da
Onari, Elton Shinji
Castro, Isac de
Perez, Marcelo Vaz
Hortensi, Alexandre
Amaral, José Luiz Gomes do
Anesthesia for muscle biopsy to test susceptibility to malignant hyperthermia
title Anesthesia for muscle biopsy to test susceptibility to malignant hyperthermia
title_full Anesthesia for muscle biopsy to test susceptibility to malignant hyperthermia
title_fullStr Anesthesia for muscle biopsy to test susceptibility to malignant hyperthermia
title_full_unstemmed Anesthesia for muscle biopsy to test susceptibility to malignant hyperthermia
title_short Anesthesia for muscle biopsy to test susceptibility to malignant hyperthermia
title_sort anesthesia for muscle biopsy to test susceptibility to malignant hyperthermia
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9391910/
https://www.ncbi.nlm.nih.gov/pubmed/31053363
http://dx.doi.org/10.1016/j.bjane.2019.02.003
work_keys_str_mv AT silvahelgacristinaalmeidada anesthesiaformusclebiopsytotestsusceptibilitytomalignanthyperthermia
AT onarieltonshinji anesthesiaformusclebiopsytotestsusceptibilitytomalignanthyperthermia
AT castroisacde anesthesiaformusclebiopsytotestsusceptibilitytomalignanthyperthermia
AT perezmarcelovaz anesthesiaformusclebiopsytotestsusceptibilitytomalignanthyperthermia
AT hortensialexandre anesthesiaformusclebiopsytotestsusceptibilitytomalignanthyperthermia
AT amaraljoseluizgomesdo anesthesiaformusclebiopsytotestsusceptibilitytomalignanthyperthermia